14-day Premium Trial Subscription Try For FreeTry Free
$4.56
-0.220 (-4.60%)
At Close: May 07, 2024
Forecast Earnings Dividends Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $0.0060 $169.56 Tuesday, 7th May 2024 ABEO stock ended at $4.56. This is 4.60% less than the trading day before Monday, 6th May 2024. During the day the stock fluctuated 11.56% from a day low at $4.54 to a day high of $5.07.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical Abeona Therapeutics Inc. prices

Date Open High Low Close Volume
Jan 08, 2014 $0.320 $0.330 $0.270 $0.300 45 000
Jan 07, 2014 $0.270 $0.320 $0.270 $0.310 120 000
Jan 06, 2014 $0.260 $0.270 $0.260 $0.270 10 000
Jan 03, 2014 $0.250 $0.260 $0.230 $0.260 15 000
Jan 02, 2014 $0.240 $0.250 $0.240 $0.250 0
Dec 31, 2013 $0.230 $0.250 $0.230 $0.250 120 000
Dec 30, 2013 $0.230 $0.260 $0.230 $0.250 70 000
Dec 27, 2013 $0.230 $0.260 $0.220 $0.260 45 000
Dec 26, 2013 $0.240 $0.240 $0.230 $0.230 25 000
Dec 24, 2013 $0.230 $0.250 $0.210 $0.240 90 000
Dec 23, 2013 $0.250 $0.260 $0.230 $0.260 80 000
Dec 20, 2013 $0.260 $0.260 $0.240 $0.250 25 000
Dec 19, 2013 $0.250 $0.270 $0.240 $0.270 20 000
Dec 18, 2013 $0.250 $0.270 $0.250 $0.270 25 000
Dec 17, 2013 $0.260 $0.280 $0.240 $0.270 120 000
Dec 16, 2013 $0.280 $0.280 $0.260 $0.280 20 000
Dec 13, 2013 $0.270 $0.270 $0.270 $0.270 30 000
Dec 12, 2013 $0.260 $0.290 $0.260 $0.290 100 000
Dec 11, 2013 $0.260 $0.280 $0.260 $0.260 25 000
Dec 10, 2013 $0.260 $0.290 $0.250 $0.280 90 000
Dec 09, 2013 $0.260 $0.290 $0.260 $0.290 65 000
Dec 06, 2013 $0.250 $0.260 $0.250 $0.260 15 000
Dec 05, 2013 $0.270 $0.270 $0.250 $0.270 105 000
Dec 04, 2013 $0.250 $0.270 $0.250 $0.270 15 000
Dec 03, 2013 $0.260 $0.280 $0.250 $0.270 85 000
Click to get the best stock tips daily for free!

About Abeona Therapeutics Inc.

Abeona Therapeutics. Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease;... ABEO Profile

Golden Star

Ticker Date Change Price
BBCA May 03 1.26% $65.44
ADTH May 03 5.56% $3.24
ISTB May 03 0.0425% $47.11
WMT May 03 1.34% $59.82
UNP May 03 0.84% $240.36
INGR May 03 1.75% $114.56
ASH May 03 2.26% $95.85
WU May 03 0.449% $13.37
INVH May 03 1.72% $34.39
INTU May 03 1.89% $629.27
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT